Cargando…

IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population

Patients who survive sepsis can develop long-term immune dysfunction, with expansion of the regulatory T (Treg) cell population. However, how Treg cells proliferate in these patients is not clear. Here we show that IL-33 has a major function in the induction of this immunosuppression. Mice deficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Nascimento, Daniele C., Melo, Paulo H., Piñeros, Annie R., Ferreira, Raphael G., Colón, David F., Donate, Paula B., Castanheira, Fernanda V., Gozzi, Aline, Czaikoski, Paula G., Niedbala, Wanda, Borges, Marcos C., Zamboni, Dario S., Liew, Foo Y., Cunha, Fernando Q., Alves-Filho, Jose C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382289/
https://www.ncbi.nlm.nih.gov/pubmed/28374774
http://dx.doi.org/10.1038/ncomms14919
Descripción
Sumario:Patients who survive sepsis can develop long-term immune dysfunction, with expansion of the regulatory T (Treg) cell population. However, how Treg cells proliferate in these patients is not clear. Here we show that IL-33 has a major function in the induction of this immunosuppression. Mice deficient in ST2 (IL-33R) develop attenuated immunosuppression in cases that survive sepsis, whereas treatment of naive wild-type mice with IL-33 induces immunosuppression. IL-33, released during tissue injury in sepsis, activates type 2 innate lymphoid cells, which promote polarization of M2 macrophages, thereby enhancing expansion of the Treg cell population via IL-10. Moreover, sepsis-surviving patients have more Treg cells, IL-33 and IL-10 in their peripheral blood. Our study suggests that targeting IL-33 may be an effective treatment for sepsis-induced immunosuppression.